Modulating a critical inhibitory proteoglycan receptor to promote functional recovery after stroke
调节关键的抑制性蛋白聚糖受体以促进中风后的功能恢复
基本信息
- 批准号:10112316
- 负责人:
- 金额:$ 35.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-15 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAnimal ModelAnimalsAreaAxonBehavioralBrainCause of DeathCellsCerebral IschemiaChondroitin SulfatesChronic PhaseCicatrixClinical TreatmentComplementContralateralCorpus striatum structureCorticospinal TractsDataDistalDoseEdemaExtracellular MatrixFamilyFiberFibrinolytic AgentsFutureGeneticGoalsHistologicHourHumanImmunohistochemistryInfarctionInflammatoryInjectionsInjuryKnock-outKnockout MiceLabelLeadLesionMammalsMeasuresMediatingMiddle Cerebral Artery OcclusionMolecularMolecular AnalysisMusNatural regenerationNerve RegenerationNeural InhibitionNeurogliaNeuronsPathway interactionsPeptidesPharmacologyPlayProcessProteoglycanRecoveryRecovery of FunctionRegulationResearchResourcesRoleRouteSeriesSignal PathwaySignal TransductionSocietiesSolidStrokeSurvival RateSynapsinsTechniquesTestingTherapeuticTimeTissuesTraumatic CNS injuryTreatment outcomeagedaxon regenerationaxonal sproutingbasebehavior measurementcell motilitycell typecomparative efficacyconditional knockoutdisabilityefficacy evaluationefficacy testingexperimental studyfunctional outcomesimprovedin vivoinsightjuvenile animalmigrationmolecular targeted therapiesmouse modelnestin proteinneuroblastneurogenesisnovelnovel therapeutic interventionpost strokeprecursor cellprogramsreceptorregenerativerepairedresponsestem cell migrationstem cellsstroke modelstroke recoverystroke therapytreatment strategy
项目摘要
Stroke is one of the leading causes of death and disability worldwide and places a heavy burden on the
economy in our society. Current treatment strategies for stroke primarily focus on reducing the size of ischemic
damage and on rescuing dying cells early after occurrence. Treatments, such as the use of thrombolytic
agents, are often limited by a narrow therapeutic time window. However, the regeneration of the brain after
damage is still active days, or even weeks after stroke occurs, which might provide a second window for
treatment. Our preliminary data suggests that systemic in vivo delivery of a peptide that blocks a specific receptor
mediated inhibitory action of sulphated proteoglycans in the glial scar in stroke animals 24 hours after stroke or 7 days
after stroke both improve their functional recovery. We hypothesize that the CSPG signaling pathway is involved
in the regulation of neuroregeneration and axonal sprouting after stroke and that modulating the CSPG
signaling pathway will lead to better functional outcome in stroke recovery. We will test this hypothesis in both
young and aged mice in the proximal transient middle cerebral artery occlusion (MCAo) animal model. Towards
this goal, we have developed a proposal that consists of three specific aims. In specific aim 1 and 2, we will
investigate the role of the CSPGs signaling pathway in functional recovery in young or aged stroke animals. In
specific aim 3, we will examine the mechanisms of neurorepair in stroke animals by combination of genetic and
pharmacological modulation with inducible cell type specific RPTPσ knockout or ISP peptide treatment. Two
main mechanisms of neurorepair including neurogenesis and axonal sprouting in stroke will be analyzed in
genetically and pharmacologically modulated stroke animals. Together, the comprehensive analysis of
molecular, cellular and behavioral measurements in stroke animals will generate data that will provide insights
on the precise role of CSPG signaling in the process of injury-induced neurorepair. The data gained will be
directly applicable to developing novel therapeutic interventions in treating cerebral ischemia through the
manipulation of the cellular microenvironment in the CNS. We anticipate that the resources and results
generated from our study will open new avenues in neuroregeneration research and lead to the identification of
molecular therapeutic targets.
中风是全世界死亡和残疾的主要原因之一,给人们带来沉重负担
当前中风的治疗策略主要集中在减少缺血性病变的范围。
损害以及在发生后尽早挽救垂死的细胞。
然而,药物治疗后的大脑再生往往受到狭窄的治疗时间窗口的限制。
中风发生后数天甚至数周,损伤仍然活跃,这可能提供第二个窗口期
我们的初步数据表明,系统性体内递送肽可阻断特定受体。
中风后 24 小时或 7 天,硫酸化蛋白多糖在中风动物神经胶质疤痕中介导的抑制作用
我们发现 CSPG 信号通路参与了中风后的功能恢复。
中风后神经再生和轴突萌芽的调节以及 CSPG 的调节
信号通路将在中风恢复中带来更好的功能结果,我们将在这两种情况下检验这一假设。
近端短暂大脑中动脉闭塞(MCAo)动物模型中的年轻和老年小鼠。
为了实现这一目标,我们制定了一项由三个具体目标组成的提案,在具体目标 1 和 2 中,我们将。
研究 CSPG 信号通路在年轻或老年中风动物功能恢复中的作用。
具体目标3,我们将通过结合遗传和中风动物的神经修复机制来研究中风动物的神经修复机制。
通过诱导细胞类型特异性 RPTPσ 敲除或 ISP 肽治疗进行药理调节 两种。
神经修复的主要机制,包括中风中的神经发生和轴突萌芽,将在以下章节中进行分析
遗传和药理调节中风动物的综合分析。
中风动物的分子、细胞和行为测量将生成可提供见解的数据
所获得的数据将是关于 CSPG 信号在损伤诱导的神经修复过程中的精确作用。
直接适用于开发治疗脑缺血的新型治疗干预措施
我们预计中枢神经系统细胞微环境的资源和结果。
我们的研究产生的结果将为神经再生研究开辟新途径,并导致识别
分子治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yu Luo其他文献
Yu Luo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yu Luo', 18)}}的其他基金
Investigating the role of CSF production and circulation in aging and Alzheimer's disease
研究脑脊液产生和循环在衰老和阿尔茨海默病中的作用
- 批准号:
10717111 - 财政年份:2023
- 资助金额:
$ 35.07万 - 项目类别:
The role TGF-beta Signaling pathway in microglia and astrocytes homeostasis and cellular interactions
TGF-β信号通路在小胶质细胞和星形胶质细胞稳态和细胞相互作用中的作用
- 批准号:
10538929 - 财政年份:2022
- 资助金额:
$ 35.07万 - 项目类别:
The role TGF-beta Signaling pathway in microglia and astrocytes homeostasis and cellular interactions
TGF-β信号通路在小胶质细胞和星形胶质细胞稳态和细胞相互作用中的作用
- 批准号:
10620319 - 财政年份:2022
- 资助金额:
$ 35.07万 - 项目类别:
Modulating a critical inhibitory proteoglycan receptor to promote functional recovery after stroke
调节关键的抑制性蛋白聚糖受体以促进中风后的功能恢复
- 批准号:
10380110 - 财政年份:2019
- 资助金额:
$ 35.07万 - 项目类别:
Modulating a critical inhibitory proteoglycan receptor to promote functional recovery after stroke
调节关键的抑制性蛋白聚糖受体以促进中风后的功能恢复
- 批准号:
9906279 - 财政年份:2019
- 资助金额:
$ 35.07万 - 项目类别:
Derivation and dopaminergic differentiation of human drug addict-specific iPS cel
人吸毒者特异性 iPS 细胞的衍生和多巴胺能分化
- 批准号:
8324558 - 财政年份:2011
- 资助金额:
$ 35.07万 - 项目类别:
Derivation and dopaminergic differentiation of human drug addict-specific iPS cel
人吸毒者特异性 iPS 细胞的衍生和多巴胺能分化
- 批准号:
8247948 - 财政年份:2011
- 资助金额:
$ 35.07万 - 项目类别:
相似国自然基金
探索在急性呼吸窘迫综合征动物模型和患者长时间俯卧位通气过程中动态滴定呼气末正压的意义
- 批准号:82270081
- 批准年份:2022
- 资助金额:76 万元
- 项目类别:面上项目
建立脑内急性基因编辑的孤独症非人灵长类动物模型
- 批准号:
- 批准年份:2019
- 资助金额:100 万元
- 项目类别:专项基金项目
染色体大片段缺失的急性髓性白血病动物模型的构建及分析
- 批准号:81770157
- 批准年份:2017
- 资助金额:84.0 万元
- 项目类别:面上项目
树鼩异种移植模型的建立及免疫排斥机制的深入研究
- 批准号:81771721
- 批准年份:2017
- 资助金额:80.0 万元
- 项目类别:面上项目
自发性高甘油三酯急性胰腺炎大鼠模型的建立及应用
- 批准号:81570584
- 批准年份:2015
- 资助金额:85.0 万元
- 项目类别:面上项目
相似海外基金
A Refined Murine Model of Post-sepsis Cognitive Impairment for Investigating Mitochondrial Abnormalities and Human ApoE4 Gene Polymorphisms
用于研究线粒体异常和人类 ApoE4 基因多态性的精制脓毒症后认知障碍小鼠模型
- 批准号:
10646579 - 财政年份:2023
- 资助金额:
$ 35.07万 - 项目类别:
The Injectrode- An injectable, easily removable electrode as a trial lead for baroreceptor activation therapy to treat hypertension and heart failure
Injectrode——一种可注射、易于拆卸的电极,作为压力感受器激活疗法的试验引线,以治疗高血压和心力衰竭
- 批准号:
10697600 - 财政年份:2023
- 资助金额:
$ 35.07万 - 项目类别:
Achieving Sustained Control of Inflammation to Prevent Post-Traumatic Osteoarthritis (PTOA)
实现炎症的持续控制以预防创伤后骨关节炎 (PTOA)
- 批准号:
10641225 - 财政年份:2023
- 资助金额:
$ 35.07万 - 项目类别:
Project 1: Translational Studies on Temperature and Solvent Effects on Electronic Cigarette-Derived Oxidants
项目1:温度和溶剂对电子烟氧化剂影响的转化研究
- 批准号:
10665896 - 财政年份:2023
- 资助金额:
$ 35.07万 - 项目类别:
Oxidative Stress and Mitochondrial Dysfunction in Chemogenetic Heart Failure
化学遗传性心力衰竭中的氧化应激和线粒体功能障碍
- 批准号:
10643012 - 财政年份:2023
- 资助金额:
$ 35.07万 - 项目类别: